Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on developing life-saving medicines, has announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on developing life-saving medicines, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Mike Andriole, the company's CEO, will deliver a corporate presentation on September 9, 2024, at 7:00 a.m. ET.
The presentation will be made available as an audio webcast on the Investor Relations section of Chimerix's website at ir.chimerix.com. Interested parties can access the webcast, which will remain archived on the site for approximately 90 days. This event provides an opportunity for investors and analysts to gain insights into Chimerix's latest developments and future strategies.
Details
News Market Reaction – CMRX
The recorded move for CMRX in the trading session of this news was -7.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will present a corporate presentation at the H.C. Wainwright 26th Annual Global Investment Conference made available on Monday, September 9, 2024 at 7:00 a.m. ET.
An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.
CONTACT:
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.